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Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is
responsible for the current COVID-19 disease pandemic. In some
patients, the symptoms are mild, and a fraction of SARS-CoV-2-
infected individuals develop severe illness with a high fatality rate
due to lung damage and acute respiratory distress syndrome.1
Innate lymphoid cells (ILCs) are a recently identified type of
effector immune cells that rapidly sense environmental stimuli
and participate in early immune responses by promptly secreting
large amounts of cytokines.2 The ILC2 subpopulation was shown
to mediate Type 2 responses and to recruit eosinophils during
viral lung infections upon the release of alarmins (e.g., IL-33) by
damaged epithelial cells.3–5 ILC2s were also shown to participate
in the termination of inflammatory responses and tissue repair by
amphiregulin secretion. In addition, ILC2s are critical in the early
phases of allergic lung inflammation, including that induced by
the protease allergen papain.6 Based on the essential function of
the papain-like protease PLpro in regulating SARS-CoV-27 (Fig. 1a)
and the severe lung damage caused by this virus, we sought to
investigate the potential involvement of ILC2s in immune
responses to COVID-19.
As an initial proof of concept, we intranasally administered the
papain-like protease PLpro in wild-type animals for 5 consecutive
days (Fig. 1a). We observed a rapid increase in the total ILC and
ILC2 numbers in the lungs. The percentage of IL-5+ ILC2s was
increased upon papain challenge, which was concomitant with
increased eosinophil infiltration (Fig. 1a) and compatible with
PLpro-dependent ILC2 triggering.
Based on these observations, we next explored a retrospective
cohort of 60 COVID-19 convalescent patients (mild n= 30, severe
n= 30) previously described in Kroemer et al.8 Since plant-derived
papain is known to act by stimulating epithelial cells to secrete IL-
33,9 we hypothesized a similar mechanism for PLpro and
quantified IL-33 in the sera of the patients. We observed a
significant increase in IL-33 in COVID-19 patients compared to that
in healthy donors (HDs), suggesting that in humans, PLpro might
drive alarmin secretion (Fig. 1b). Next, by performing multi-
parametric flow cytometry-based immune monitoring of circulat-
ing ILCs, defined as Lin−CD127+ cells, we detected a reduction in
total ILCs in severely ill patients, with a significant relative increase
in the ILC2 subpopulation but no significant changes in other
subpopulations (Fig. 1b). The proportions of cKithigh and cKitdim
ILC2s were comparable between HDs and mild COVID-19 patients.
However, the cKitdim subset was expanded in severe patients,
which was compatible with an increase in fully mature ILC2s.
Furthermore, we observed overall low but elevated levels of the
Type 2 cytokines IL-5 and IL-13 in patients compared to those in
HDs (Fig. 1b), while Type 1 and Type 17 cytokine levels were
comparable across cohorts (data not shown). In line with the
current literature, IL-6 levels were also increased in severe COVID-
19 patients.
Upon activation, ILC2s modulate their phenotype by up/
downregulating cell surface proteins. Therefore, we screened the
expression of activating and inhibitory receptors on ILC2s in mild
and severe patients. The ILC2s in severe patients showed an
increase in the NKG2D+ population compared to those in mild
patients and controls and a significant decrease in CD25 and
KLRG1 (Fig. 1c). No differences in NKG2D, KLRG1, or CD25
expression were observed in ILC1s or ILCPs in patients (data not
shown). The levels of other markers, such as PD-1, NKG2A, and
NKp46, were similar on ILC2s from HDs and patients.
Of note, NKG2D, which is the activating C-type lectin-like molecule
abundantly expressed by cytotoxic NK cells, has not been previously
reported on ILC2s. However, its expression is known to be induced in
NK cells by IL-33 and other members of the IL-1 family of cytokines,
such as IL-18. Notably, serum IL-18 levels were significantly higher in
severe COVID-19 patients than in patients with mild illness and HDs
(Fig. 1d). Furthermore, ILC2s were previously reported to express
IL-18R in the skin, lung and bone marrow10 and to react to IL-18
produced by Type 2 cytokine secretion. To verify whether NKG2D
expression in ILC2s can be induced by elevations of the IL-33 or IL-18
concentrations in COVID-19 patients (Fig. 1b, d), we stimulated HD
peripheral blood mononuclear cells (PBMCs) in vitro with recombi-
nant human (rh) IL-33 or rhIL-18 alone or in combination for 48 h and
monitored the ILC2 phenotype. We observed an increase in NKG2D
expression in ILC2s exposed to IL-18 (Fig. 1d) but not in ILC2s
exposed to IL-33, suggesting a direct link between IL-18 and
NKG2D+ ILC2s in severe COVID-19 patients. To explore the potential
clinical relevance of NKG2D+ ILC2s in anti-COVID-19 immune
responses, we stratified patients based on the median expression
of NKG2D on ILC2s (Fig. 1e). We observed a significantly reduced
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proportion of patients requiring mechanical ventilation in the severe
group with high numbers of NKG2D+ ILC2s, indicating the protective
role of this cell subset in the response against the virus. In line with
this finding, the hospitalization length was drastically reduced in
these patients (Fig. 1e).
Overall, our study shows an increase in ILC2s in COVID-19
patients in parallel with elevated serum Type 2 cytokine levels.
These anti-inflammatory mediators might be produced particu-
larly by NKG2D+ ILC2s upon engagement of the NKG2D receptor
with its ligands, which are known to be upregulated on infected
cells in the context of viral diseases.
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Fig. 1 ILC2 increases and NKG2D expression in COVID-19 patients. a Lung cell numbers (total ILCs, ILC2s, and eosinophils) and the frequencies
of IL-5+ ILC2s in WT animals treated intranasally with SARS-CoV-2 PLpro vs those in untreated animals. b Percentages of total ILCs and ILC
subsets in PBMCs in HDs vs those in COVID-19 patients and serum cytokine levels in HDs vs COVID-19 patients. c Phenotyping of ILC2s in
PBMCs of HDs and mild and severe COVID-19 patients. Percentages of positive ILC2s and the mean fluorescence intensity (MFI) of NKG2D,
CD25, KLRG1, and PD-1 are shown. d Serum levels of IL-18 in HDs vs those in COVID-19 patients (upper part) and NKG2D expression and the
MFI in HD PBMCs after 48 h of in vitro cytokine stimulation with hrIL-18, hrIL-33 or both vs those in unstimulated cells. e Clinical characteristics
of severely ill COVID-19 patients classified as NKGD2hi and NKGD2low based on the median expression of NKG2D on ILC2s in the total
patient cohort
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